I researched the Johnson & Johnson baby powder controversy for three months after a relative asked me if it was safe for her newborn. I expected a simple yes or no. I got a story about geology, litigation, regulatory gaps, and scientific uncertainty. Johnson & Johnson stopped selling talc-based baby powder in the U.S. in 2020 and globally in 2023. But the questions keep coming. Is the product safe? Was it ever safe? And what should parents use instead? This is what the science actually says in 2026.
The Core Issue: Talc and Asbestos Are Geologically Related
Talc is a mineral. Asbestos is a group of minerals. They form under similar geological conditions and are often found near each other in the earth. The question is not whether talc is inherently dangerous. It is whether mined talc can be contaminated with asbestos fibers during extraction.
The FDA has tested cosmetic talc products since 2019. Of 52 products tested, 9 contained asbestos. Johnson & Johnson’s own testing found no asbestos in their talc, but independent labs and plaintiffs’ experts disputed those findings in court. The scientific consensus is nuanced: asbestos-free talc is likely safe, but ensuring asbestos-free status at scale is difficult.
What the Epidemiological Studies Show
The evidence on talc and ovarian cancer is mixed but concerning. A 2020 meta-analysis by the National Cancer Institute found a small increased risk of ovarian cancer with perineal talc use, but noted significant methodological limitations in the underlying studies. The International Agency for Research on Cancer (IARC) classifies perineal talc use as “possibly carcinogenic to humans” (Group 2B) — the same category as aloe vera extract and pickled vegetables.
The key phrase is “possibly carcinogenic.” This is not a causal determination. It means the evidence is limited and more research is needed. But it is not a clean bill of health either.
Why Johnson & Johnson Stopped Selling Talc Powder
J&J faced over 40,000 lawsuits alleging that talc caused ovarian cancer and mesothelioma. In 2021, the company set aside $3.9 billion for settlements. In 2023, they filed for bankruptcy through a subsidiary, LTL Management, to manage the litigation. The legal strategy was controversial and eventually blocked by courts.
The decision to stop selling talc powder was likely driven by legal and reputational risk, not a definitive scientific finding of harm. The company now sells a cornstarch-based alternative.
What Parents Should Use Instead
- Cornstarch-based powders: J&J and other brands offer these. They absorb moisture without the talc/asbestos concern.
- No powder at all: The American Academy of Pediatrics recommends against routine powder use. Diaper rash is better prevented with barrier creams (zinc oxide) and frequent changes.
- Arrowroot powder: A natural alternative for parents who want a powder texture without talc or cornstarch.
Key Takeaways
- Talc and asbestos are geologically related. Contamination is possible but not inevitable.
- The evidence linking talc to ovarian cancer is limited and contested. IARC classifies it as “possibly carcinogenic.”
- Johnson & Johnson stopped selling talc powder due to legal risk, not a definitive scientific verdict.
- Cornstarch-based powders and barrier creams are safer alternatives.
- The AAP recommends against routine powder use for infants.
Frequently Asked Questions
Is all talc dangerous?
Asbestos-free talc is likely safe. The risk comes from potential asbestos contamination during mining. The challenge is verifying asbestos-free status at scale.
Can I still buy J&J talc powder?
Not from J&J directly. Some third-party sellers may have old stock. The company has transitioned entirely to cornstarch-based products.
What is the safest option for diaper rash?
Zinc oxide barrier cream and frequent diaper changes. Powders are not recommended by the AAP for routine use.
Should I worry if I used talc powder in the past?
The absolute risk increase, if real, is small. Consult your doctor if you have specific concerns. Routine screening for ovarian cancer is not recommended for average-risk women.
